Genomic Study Maps Shared Risk Factors for 14 Psychiatric Disorders
December 14, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Triptodur
(United States) [Available] ,Trelstar Mixject
(United States) [Available]Synonyms :
Triptorelin
Class :
Class: Antineoplastics and Sub class: GnRH Agonist
Brand Name :
Triptodur
(United States) [Available] ,Trelstar Mixject
(United States) [Available]Synonyms :
Triptorelin
Class :
Class: Antineoplastics and Sub class: GnRH Agonist
Dosage Forms & Strengths:
lyophilized powder for reconstitution
Reconstitution results in suspension for IM injection
3.75 mg per vial
11.25 mg per vial
22.5 mg per vial
3.75
mg
Intramuscular (IM)
4
weeks
or 11.25 mg shown IM for every 12 weeks, or 22.5 mg given IM for every 24 weeks
Dose Adjustments
Renal Dose Adjustments:
There is no adjustment recommended
Liver Dose Adjustments:
There is no adjustment recommended
Dosage Forms & Strengths:
lyophilized powder for reconstitution
22.5mg/vial; reconstitution results in suspension for IM injection
The kit is for single use and contains a drug vial, prefilled diluent syringe, and 21-gauge needle
The dose recommended for >2years is 22.5 mg given IM every 24 weeks
Dose Adjustments
Renal Dose Adjustments:
There is no adjustment recommended
Liver Dose Adjustments:
There is no adjustment recommended
CYP3A Inhibitors: they may diminish the serum concentration of hormonal agents
CYP3A Inhibitors: they may diminish the serum concentration of hormonal agents
CYP3A Inhibitors: they may diminish the serum concentration of hormonal agents
CYP3A Inhibitors: they may diminish the serum concentration of hormonal agents
CYP3A Inhibitors: they may diminish the serum concentration of hormonal agents
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be a decreased therapeutic efficacy of mifepristone
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
indium In-111 capromab pendetide
may decrease the diagnostic effect when combined
indium In-111 capromab pendetide
may decrease the diagnostic effect when combined
may decrease the level by affecting hepatic enzyme CYP3A4 metabolism
may decrease the level by affecting hepatic enzyme CYP3A4 metabolism
may decrease the level by affecting hepatic enzyme CYP3A4 metabolism
may decrease the level by affecting hepatic enzyme CYP3A4 metabolism
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be a decreased therapeutic efficacy of albiglutide
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be a decreased therapeutic efficacy of alogliptin
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
it may enhance the risk of QTc prolongation when combined with amifampridine
when both drugs are combined, there may be a decreased therapeutic efficacy of sulfamethoxazole
Triptorelin is a synthetic analog of gonadotropin-releasing hormone (GnRH) that acts as an agonist. In animal studies, it demonstrated significantly greater potency than natural GnRH, showing a 13-fold increase in luteinizing hormone release and a 21-fold increase in follicle-stimulating hormone release.
Adverse drug reactions:
Frequency defined
1-10%
Cough
Diarrhea
Fatigue
Generalized pain
Headache
Hot flushes
Hypertension
Impotence
Injection site pain
Injection site pruritus
Injection site swelling
Insomnia
Pruritus
Spinal cord compression
UTI
Upper respiratory infection
Vaginal bleeding
Vomiting
>10%
Headache
Hot flushes
Injection site pain
Injection site redness
Nasopharyngitis
Skeletal pain
Tumor flare in prostate cancer patients (initial worsening of symptoms due to transient hormone surge).
Hyperglycemia and diabetes risk.
Cardiovascular risks, including increased risk of heart attack, sudden cardiac death, and stroke.
Psychiatric effects, such as mood swings and depression.
Decreased bone mineral density with long-term use.
Contraindications
Known hypersensitivity to triptorelin or GnRH analogues.
Pregnancy and breastfeeding.
Cautions
May cause osteoporosis with long-term use due to hypoestrogenism/hypogonadism.
Monitor bone density in prolonged therapy.
Use with caution in patients with cardiovascular disease, diabetes, or seizure disorders.
May cause menopausal symptoms (hot flashes, mood changes).
Patients should be monitored for psychological effects such as depression.
Pregnancy warnings:
Breastfeeding warnings:
Pregnancy Categories:
Triptorelin is a synthetic gonadotropin-releasing hormone (GnRH) agonist. Its pharmacological action involves an initial stimulation of the pituitary gland, leading to a transient surge in the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This results in a temporary increase in sex hormones—testosterone in males and estrogen in females. However, with continued administration, triptorelin causes downregulation of GnRH receptors in the pituitary, suppressing LH and FSH secretion. Consequently, this leads to a significant reduction in circulating testosterone and estrogen levels. This hormonal suppression is therapeutically beneficial in hormone-dependent conditions such as prostate cancer, breast cancer, and central precocious puberty, where lowering sex hormone levels helps inhibit disease progression.
Intramuscular (IM) or subcutaneous (SC) injection
It is commonly given as depot injections every 1, 3, or 6 months
Generic Name: triptorelin
Pronunciation: TRIP-toe-REL-in
Why do we use triptorelin?
Triptorelin is a synthetic hormone used to regulate hormonal activity in the body. Its clinical applications vary by formulation:
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
